Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-03-21 00:00:00 ET · period of report 2023-03-17 · accession 0001827564-23-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-03-21 | 2023-03-17+ | TARS | Holdbrook Mark J. | VP, Clinical Affairs | S - Sale | $12.94 | -386 | 3,389 | -10% | -$4,993 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-20 | S | D | 198 | $12.61 | 3,191 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-17 | S | D | 188 | $13.28 | 3,389 | D | — | — |